Meadowcroft AM, et al. - This study was designed to assess the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease. In patients on hemodialysis (HD), daprodustat-induced dose-dependent changes in hemoglobin were seen over the first 4 weeks after switching from a stable dose of recombinant human erythropoietin (rhEPO). Moreover, daprodustat maintained hemoglobin target levels over 24 weeks in these patients.